MedTrace Logo

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2026-04-08

No results posted yet for this study

Summary

The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults.

Participants will receive either:

* an experimental PG4 vaccine
* a PG4 vaccine comparator
* a standard 20vPnC vaccine comparator
* placebo. A placebo does not have any medicine in it but looks just like the study medicine.

Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits.

At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.

Conditions

  • Streptococcus Pneumoniae

Interventions

BIOLOGICAL

PG4 vaccine in Buffer 1 with low dose PA-001

Multivalent pneumococcal conjugate vaccine

BIOLOGICAL

PG4 in Buffer 1 with low dose PA-002

Multivalent pneumococcal conjugate vaccine

BIOLOGICAL

PG4 in Buffer 1 with high dose PA-001

Multivalent pneumococcal conjugate vaccine

BIOLOGICAL

PG4 vaccine in Buffer 1 with high dose PA-002

Multivalent pneumococcal conjugate vaccine

BIOLOGICAL

PG4 vaccine in Buffer 2

Multivalent pneumococcal conjugate vaccine

BIOLOGICAL

20-valent pneumococcal conjugate vaccine

(20vPnC)

BIOLOGICAL

Saline injection

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-22
Primary Completion
2027-10-21
Completion
2027-10-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07086677 on ClinicalTrials.gov